Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORNBILL: BI 764524 in PDR with DMI
NCT04424290Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2020
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of BI 764524 in diabetic macular ischemia (DMI), proliferative diabetic retinopathy (PDR), sponsored by Boehringer Ingelheim. Started Jun 2020; status: completed.
02
Drugs
BI 764524
03
Conditions
diabetic macular ischemia (DMI)proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT04424290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04424290.